WSTAM
NBRV

Wilbanks Smith & Thomas Asset Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-120
Closed -$44K – 426
2018
Q4 		$44K Hold
120
– – ﹤0.01% 353
2018
Q3 		$81K Buy
+120
New +$85.1K ﹤0.01% 591

Other funds holding NBRV

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's NBRV Position: Q1 2019 in Review

Wilbanks Smith & Thomas Asset Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2019, closing a stake of 120 shares — an estimated $44K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in NBRV in Q3 2018 and held it in 2 quarters. The position peaked at $81K in Q3 2018. 39 funds tracked by Wall St. Rank hold NBRV as of Q1 2019.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2019 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 120 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2019, an estimated $44K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2018 and held it in 2 quarters.
  • Wilbanks Smith & Thomas Asset Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $81K in Q3 2018.
  • 39 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2019.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2019, filed 13 May 2019.